EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary AMLs will be held April 25-26, 2025 at Berlin, Germany.
The EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias (sAML) will focus on therapy-related AML and AML evolving from previous myeloid diseases, such as MDS or MFS/MPN. Key topics will include clonal hematopoiesis, clonal evolution mechanisms, and special clinical situations.
The program will cover pathogenetic mechanisms, including susceptibility factors like molecular lesions, the bone marrow microenvironment, and the impact of drugs. Special topics include sAML following childhood malignancies, gene therapy, CAR-T cell therapy, and AML of donor origin in allogeneic stem cell transplantation. The meeting will feature leading experts in sAML molecular characterization, disease diagnosis, management, and treatment. The event will be chaired by K. Döhner, P. Vyas, and M.T. Voso.
Registration is open.
